Search results
Jan 6, 2022 · This very generous grant will fast-forward our translation of basic discoveries to clinical trials, ultimately providing innovative treatments for patients and their families,” said Ken Anderson, MD, program director at Dana-Farber’s Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics and Kraft Family ...
Ken Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, was in Washington, D.C., on Feb. 12, to speak with members of Congress and their legislative staffs about blood cancer care and research.
Oct 7, 2014 · Dana-Farber is one of nine beneficiaries of the 2013 event. Shoes for sale included those by Enzo Angiolini, Bandolino, Anne Klein, Via Spiga, Etienne Mark Kieran Ken Anderson Esther Obeng Jimmy Fund Clinic patients skate with the stars Dana-Farber Jimmy Fund Clinic patient Nora Rozgony, 8, of Broomfield,
8 Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. kenneth_anderson@dfci.harvard.edu. PMID: 35082402 DOI: 10.1038/s41375-021-01475-z
Apr 25, 2018 · Boston, MA. Kenneth C Anderson, MD, PhD, is the Kraft Family Professor of Medicine at Harvard Medical School as well as Program Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at the Dana-Farber Cancer Institute. Additionally, Dr Anderson is a Doris Duke Distinguished Clinical Research ...
Investment in talent is one of the most important ways to accelerate scientific discovery, and the Sherwoods have long known that support of “human capital” is key to keeping Dana-Farber at the forefront of cancer medicine. “We have been giving to further Ken’s multiple myeloma research since 1998,” said Ned Sherwood.
877-442-3324. REQUEST AN APPOINTMENT. Our program encompasses physicians, clinicians, and a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies. It is part of the Division of Plasma Cell Neoplasias, focused on research and clinical care for plasma cell disorders.
